Binni Kunvarjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Binni Kunvarjee has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Andromachi Scaradavou
Associate Attending, Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065
2 shared publications - Jaap Jan Boelens
Memorial Sloan Kettering Cancer Center
2 shared publications Kevin J. Curran
Pediatric Bone Marrow Transplant and Cellular Therapies, MSK Kids Memorial Sloan Kettering Cancer Center New York New York USA
2 shared publications- Maria Cancio
Stem Cell Transplantation and Cellular Therapy, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY
2 shared publications Akshay Sharma
Department of Bone Marrow Transplantation and Cellular Therapy St. Jude Children's Research Hospital Memphis Tennessee USA
1 shared publicationAlexandra Budhai
Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York New York USA
1 shared publication
Latest Publications
- 19 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1471.e1-1471.e9
Association of a Digital Clinical Decision Support Platform With Early Outcomes After Pediatric Allogeneic Hematopoietic Cell Transplantation: A Three-Era Guideline Implementation Cohort Study
- 19 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1471.e1-1471.e9
Association of a Digital Clinical Decision Support Platform With Early Outcomes After Pediatric Allogeneic Hematopoietic Cell Transplantation: A Three-Era Guideline Implementation Cohort Study
- Open Access
- 11 January 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1540-1544
Donor‐specific antibody desensitization with daratumumab prior to haematopoietic cell transplant for sickle cell disease: A case report
- 11 January 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1540-1544
Open AccessDonor‐specific antibody desensitization with daratumumab prior to haematopoietic cell transplant for sickle cell disease: A case report
- 29 September 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (1) , 23-33
T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML
The only curative approach for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) arising in patients with Fanconi anemia (FA) is allogeneic hematopoietic stem cell transplantation (HCT); however, HCT approaches are inconsistent and limited data on outcomes exist. We retrospectively evaluated outcomes of thirty patients with FA and MDS/AML who underwent first allogeneic HCT with a T-cell depleted (TCD) graft at our institution. Patients were transplanted on successive protocols with stepwise changes in cytoreduction and GVHD prophylaxis. All but two patients (93%) experienced durable hematopoietic engraftment. With median follow-up of 8.7 years, 5-year OS was 66.8% and DFS 53.8%. No significant differences in survival were found in patients with high-risk prognostic features (age ≥20 years, AML diagnosis, alternative donor graft) or when stratified by conditioning regimen. The 5-year cumulative incidences of relapse and NRM were 24.3% and 21.9%, respectively. NRM was higher in patients ≥20 years at HCT but did not otherwise differ. We herein demonstrate promising outcomes following allogeneic HCT for patients with FA and MDS/AML using TCD grafts, particularly in a cohort of high-risk patients with 50% ≥20 years and a majority receiving mismatched grafts. Future prospective studies are needed to compare this approach with other HCT platforms.
- 29 September 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (1) , 23-33
T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML
The only curative approach for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) arising in patients with Fanconi anemia (FA) is allogeneic hematopoietic stem cell transplantation (HCT); however, HCT approaches are inconsistent and limited data on outcomes exist. We retrospectively evaluated outcomes of thirty patients with FA and MDS/AML who underwent first allogeneic HCT with a T-cell depleted (TCD) graft at our institution. Patients were transplanted on successive protocols with stepwise changes in cytoreduction and GVHD prophylaxis. All but two patients (93%) experienced durable hematopoietic engraftment. With median follow-up of 8.7 years, 5-year OS was 66.8% and DFS 53.8%. No significant differences in survival were found in patients with high-risk prognostic features (age ≥20 years, AML diagnosis, alternative donor graft) or when stratified by conditioning regimen. The 5-year cumulative incidences of relapse and NRM were 24.3% and 21.9%, respectively. NRM was higher in patients ≥20 years at HCT but did not otherwise differ. We herein demonstrate promising outcomes following allogeneic HCT for patients with FA and MDS/AML using TCD grafts, particularly in a cohort of high-risk patients with 50% ≥20 years and a majority receiving mismatched grafts. Future prospective studies are needed to compare this approach with other HCT platforms.